JP2021509916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021509916A5 JP2021509916A5 JP2020557135A JP2020557135A JP2021509916A5 JP 2021509916 A5 JP2021509916 A5 JP 2021509916A5 JP 2020557135 A JP2020557135 A JP 2020557135A JP 2020557135 A JP2020557135 A JP 2020557135A JP 2021509916 A5 JP2021509916 A5 JP 2021509916A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- effective
- composition according
- pic1 peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022025426A JP7341268B2 (ja) | 2018-01-09 | 2022-02-22 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615183P | 2018-01-09 | 2018-01-09 | |
| US62/615,183 | 2018-01-09 | ||
| US201862681458P | 2018-06-06 | 2018-06-06 | |
| US62/681,458 | 2018-06-06 | ||
| US201862746649P | 2018-10-17 | 2018-10-17 | |
| US62/746,649 | 2018-10-17 | ||
| PCT/US2019/012659 WO2019139886A1 (en) | 2018-01-09 | 2019-01-08 | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025426A Division JP7341268B2 (ja) | 2018-01-09 | 2022-02-22 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021509916A JP2021509916A (ja) | 2021-04-08 |
| JP2021509916A5 true JP2021509916A5 (enExample) | 2021-07-26 |
| JP7031011B2 JP7031011B2 (ja) | 2022-03-07 |
Family
ID=67140101
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557135A Active JP7031011B2 (ja) | 2018-01-09 | 2019-01-08 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
| JP2022025426A Active JP7341268B2 (ja) | 2018-01-09 | 2022-02-22 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025426A Active JP7341268B2 (ja) | 2018-01-09 | 2022-02-22 | 動物モデルにおけるミエロペルオキシダーゼ酸化活性のｐｉｃ１による阻害 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US11135272B2 (enExample) |
| EP (2) | EP3740074B1 (enExample) |
| JP (2) | JP7031011B2 (enExample) |
| KR (2) | KR20220104268A (enExample) |
| CN (1) | CN112512548A (enExample) |
| AU (2) | AU2019207508B2 (enExample) |
| CA (1) | CA3086407A1 (enExample) |
| ES (1) | ES2996888T3 (enExample) |
| IL (2) | IL287308B2 (enExample) |
| MX (3) | MX2020007098A (enExample) |
| SG (1) | SG11202006063RA (enExample) |
| WO (1) | WO2019139886A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10947279B2 (en) | 2015-06-26 | 2021-03-16 | Realta Holdings, Llc | Synthetic peptide compounds and methods of use |
| US11135272B2 (en) | 2018-01-09 | 2021-10-05 | Realta Holdings, Llc | PIC1 inhibition of myeloperoxidase oxidative activity in an animal model |
| WO2022072272A2 (en) * | 2020-09-30 | 2022-04-07 | Realta Life Sciences, Inc. | Peptides and methods of use |
| MX2023005135A (es) * | 2020-11-02 | 2023-05-26 | Realta Life Sciences Inc | Peptidos y metodos de uso. |
| US20230303623A1 (en) * | 2020-11-02 | 2023-09-28 | Realta Life Sciences, Inc. | Peptides and methods of use |
| IL302567A (en) * | 2020-11-09 | 2023-07-01 | Realta Life Sciences Inc | Peptide formulations and methods of use |
| CN116981689A (zh) * | 2021-02-26 | 2023-10-31 | 马克斯·普朗克科学促进学会 | 特异性识别中性粒细胞胞外陷阱的抗裂解的组蛋白h3单克隆抗体 |
| JP2024522988A (ja) * | 2021-06-01 | 2024-06-25 | レアルタ ライフ サイエンシズ インコーポレイテッド | ペプチドおよび使用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625049A (en) | 1993-05-12 | 1997-04-29 | Us Health | Nucleic acids encoding human astrovirus serotype 2 |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| AU3066699A (en) | 1998-03-03 | 1999-09-20 | Johns Hopkins University, The | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| WO2000043027A1 (en) | 1999-01-19 | 2000-07-27 | University Of Louisville Research Foundation, Inc. | Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease |
| US6696562B1 (en) | 2000-07-10 | 2004-02-24 | The United States Of America As Represented By The Secretary Of Agriculture | Avian astrovirus |
| US7638481B2 (en) | 2003-09-05 | 2009-12-29 | University Of Louisville Research Foundation, Inc. | Treatment of spinal cord injury |
| WO2005023296A1 (en) | 2003-09-05 | 2005-03-17 | University Of Louisville Research Foundation, Inc. | Treatment of rheumatic diseases |
| US20070012617A1 (en) | 2003-09-05 | 2007-01-18 | Sadakatsu Suzuki | Method for producing micro-porous film of thermoplastic resin |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| US7381524B2 (en) | 2003-10-10 | 2008-06-03 | Wisconsin Alumni Research Foundation | Method to detect antibodies specific for type-2 turkey astrovirus |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CA2655371C (en) | 2006-06-15 | 2017-06-20 | Eastern Virginia Medical School | Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof |
| EP2069399A2 (en) | 2007-04-11 | 2009-06-17 | Pestka Biomedical Laboratories, Inc. | Interferons of rhesus and cynomolgus origin and uses thereof |
| US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| US20130183662A1 (en) * | 2010-04-22 | 2013-07-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| EP3178841B1 (en) | 2010-07-21 | 2018-09-05 | Eastern Virginia Medical School | Peptide compounds to regulate the complement system |
| US10005818B2 (en) * | 2010-07-21 | 2018-06-26 | Realta Holdings, Llc | Derivative peptide compounds and methods of use |
| WO2013138730A1 (en) | 2012-03-16 | 2013-09-19 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of c1-inhibitors |
| US10933116B2 (en) | 2015-06-26 | 2021-03-02 | Realta Holdings, Llc | Synthetic peptide compounds and methods of use |
| US11135272B2 (en) | 2018-01-09 | 2021-10-05 | Realta Holdings, Llc | PIC1 inhibition of myeloperoxidase oxidative activity in an animal model |
-
2019
- 2019-01-08 US US16/242,550 patent/US11135272B2/en active Active
- 2019-01-08 CA CA3086407A patent/CA3086407A1/en active Pending
- 2019-01-08 ES ES19738307T patent/ES2996888T3/es active Active
- 2019-01-08 EP EP19738307.8A patent/EP3740074B1/en active Active
- 2019-01-08 WO PCT/US2019/012659 patent/WO2019139886A1/en not_active Ceased
- 2019-01-08 JP JP2020557135A patent/JP7031011B2/ja active Active
- 2019-01-08 CN CN201980007577.6A patent/CN112512548A/zh active Pending
- 2019-01-08 AU AU2019207508A patent/AU2019207508B2/en active Active
- 2019-01-08 IL IL287308A patent/IL287308B2/en unknown
- 2019-01-08 KR KR1020227023661A patent/KR20220104268A/ko not_active Ceased
- 2019-01-08 EP EP24203120.1A patent/EP4464716A3/en active Pending
- 2019-01-08 KR KR1020207022678A patent/KR102420552B1/ko active Active
- 2019-01-08 SG SG11202006063RA patent/SG11202006063RA/en unknown
- 2019-01-08 MX MX2020007098A patent/MX2020007098A/es unknown
-
2020
- 2020-04-03 US US16/839,464 patent/US11020460B2/en active Active
- 2020-07-06 IL IL275867A patent/IL275867B/en unknown
- 2020-07-13 MX MX2025009095A patent/MX2025009095A/es unknown
- 2020-07-13 MX MX2025009081A patent/MX2025009081A/es unknown
-
2021
- 2021-04-30 US US17/245,213 patent/US11712462B2/en active Active
-
2022
- 2022-02-22 JP JP2022025426A patent/JP7341268B2/ja active Active
-
2023
- 2023-06-09 US US18/332,026 patent/US12257290B2/en active Active
-
2024
- 2024-07-31 AU AU2024205230A patent/AU2024205230A1/en active Pending
-
2025
- 2025-02-19 US US19/057,376 patent/US20250177492A1/en not_active Abandoned
- 2025-09-25 US US19/339,595 patent/US20260021164A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021509916A5 (enExample) | ||
| Zehender et al. | Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up | |
| EP0585705B1 (en) | Use of monoclonal antibodies to TNF to treat bacterial meningitis | |
| Mirbahari et al. | Recent progress in combination therapy of oncolytic vaccinia virus | |
| JP2016516016A5 (enExample) | ||
| JP2011528333A5 (enExample) | ||
| Nishimura et al. | Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2 | |
| CN105722852A (zh) | 用于治疗口腔粘膜炎的新型肽和类似物 | |
| JP2019206562A5 (enExample) | ||
| JP2015502389A5 (enExample) | ||
| IT8922725A1 (it) | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori | |
| US8877203B2 (en) | Composition and method for preventing and treating immune-related disorder | |
| JP2015514756A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| JP2020504131A5 (enExample) | ||
| WO2011031890A4 (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
| IL291574B2 (en) | Methods for using 5-Adenosine Diphosphate Ribose (ADPR) | |
| JP2019501925A5 (enExample) | ||
| CN109528731B (zh) | 具有协同作用治疗多发性骨髓瘤的药物组合物及其应用 | |
| JP2017508455A5 (enExample) | ||
| WO2016071431A1 (en) | A combination for cancer therapy | |
| CN115282280A (zh) | TGF-β1信号抑制剂的新用途 | |
| US7846901B2 (en) | Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P | |
| KR20210022577A (ko) | 종양 진행 제어용 또는 항 종양 면역 회복용 대식 세포 및 조사된 백혈구의 공동 배양으로부터의 상청액 | |
| Posey et al. | Cancer killers | |
| Morales et al. | Prophylaxis and therapy of an experimental bladder cancer with biological response modifiers |